Clinical Trials

New clinical trial studies stem cell transplant for primary immunodeficiency diseases

Dennis D. Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program is leading a study that uses new DNA technology that speeds up the process of screening for primary immunodeficiency diseases (PIDs) and finding an acceptable donor match for hematopoietic stem cell transplant (HSCT).

Clinical trial studies therapy for people with prostate or kidney cancer

James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading the National Cancer Institute’s participation in a clinical trial of an experimental drug called JNJ-63898081. The goal of this multicenter study is to find out if the drug is safe to use in humans and to determine the optimal dose for the second phase of the study.

Combination therapy tested in clinical trial for metastatic genitourinary cancers

Genitourinary cancers are common but difficult to treat with chemotherapy or immunotherapy alone. A new clinical trial studies two drugs that intensify the immune system’s attack on cancer cells.

Lymphoma mass before and after treatment

Phase I CAR T-cell therapy leads to years-long remissions in relapsed B-cell lymphoma patients

In a Journal of Clinical Oncology article, results of a phase I trial by CCR investigators show that CAR T-cell therapy can result in long-lasting remissions in patients with certain relapsed B-cell lymphomas. Many who had life expectancies of only six months or less during the clinical trial of the therapy, which spanned from 2009 to 2015, remain in complete remission.

Clinical trial tests immunotherapy combination for advanced HPV-associated cancers

Human papillomavirus (HPV) is the most common sexually transmitted infection. More than 30,000 cases of HPV+ cancers occur every year in the United States. CCR investigators are leading a study using a combination of 3 immunotherapy drugs to treat HPV+ cancers.

Clinical trial tests vaccine for late-stage HPV-linked tumors

The human papillomavirus (HPV) has been linked to many kinds of cancer, including cervical, uterine, vaginal, penile and oropharyngeal. For those who develop advanced HPV-linked cancer, the NIH Clinical Center has a clinical trial open to test a vaccine with and without checkpoint inhibitors to see if this treatment approach can stop tumor growth.

Lymphoma therapy drug tested as early treatment for chronic graft-versus-host disease

cGvHD can occur after a person has had a stem cell or bone marrow transplant. In some cases, the donated bone marrow/stem cells view the host's body as foreign and start to attack it. cGvHD can occur at any time after a transplant, but it's more common after the marrow/stem cells have created a new immune system in the host's body. A clinical trial is studying the lymphoma therapy drug ibrutinib to see if early treatment can prevent the most severe symptoms of cGvHD.

Combination therapy for solid tumors and small-cell cancers studied in new clinical trial

A clinical trial of a drug combination to treat solid tumors and small-cell cancers is being conducted at the NIH Clinical Center. PARP inhibitors can work better when combined with chemotherapy, such combinations can be too toxic, so this study uses a new kind of chemotherapy called PLX038 and combines it with a PARP inhibitor rucaparib to see if the combination of PLX038 and rucaparib can safely shrink solid tumors and small-cell cancers.

Clinical trial studies combination immunotherapy for colorectal cancer

Colorectal cancer (CRC) affects the colon and rectum, which are located at the lower end of the digestive tract. One of the most common cancers, it often spreads to the liver. Because treatments that aim to use the patient’s own immune system to attack mCRC have not been very successful so far, investigators are leading a study that combines two different types of immunotherapy to see if one can enhance the effect of the other.

Adapted "Schema of in vivo working model between T-cells, NK cells and macrophages and Avelumab during antitumor immune response

Clinical trial evaluates a combination therapy for metastatic clear cell renal carcinoma

Kidney cancer is the 6th most common cancer diagnosed in the United States with greater than 73,000 new cases seen each year. CCR investigators are interested in studying a combination immunotherapy for its most common subtype, clear cell renal carcinoma, using Avelumab and interleukin (IL)-15.

Breadcrumb